Investment Thesis
Cue Biopharma is an early-stage biotech company with promising 7793% revenue growth and improving EPS, but faces critical cash runway constraints. With $16.4M cash and -$11.1M annual FCF burn, the company has approximately 18 months of operating capital before requiring additional financing, creating binary execution risk.
Strengths
- Zero debt with clean balance sheet (Debt/Equity: 0.00x); no debt service burden
- Exceptional liquidity position with 3.57x current and quick ratios; can easily cover near-term obligations
- Dramatic 7793.6% YoY revenue growth and improving diluted EPS (61.1% YoY improvement) suggest early commercialization traction
- Reasonable stockholders' equity base of $21.6M provides solvency cushion
Risks
- Critical cash runway of ~18 months at current -$11.1M FCF burn rate; requires near-term funding or profitability achievement
- Deeply unprofitable with -91.1% net margin and -94.1% operating margin; no visible path to profitability in near term
- Early-stage biotech with $5.7M revenue base faces high binary clinical and commercial execution risk; limited margin for error
- Negative operating cash flow of -$10.9M indicates operations are cash-consumptive and company is not self-sustaining
- Future funding likely to cause significant shareholder dilution to extend runway beyond 18-month horizon
Key Metrics to Watch
- Quarterly cash burn rate and estimated cash runway; any extension of operating expenses increases dilution risk
- Revenue growth sustainability and product commercialization progress; growth trajectory determines cash consumption period
- Clinical trial outcomes and regulatory milestone achievements; critical for demonstrating value in future funding rounds
- Operating expense management and cost control; ability to extend cash runway without revenue growth
- Capital raise timing, size, and dilution impact; necessity and terms of future financing indicate investor confidence
Financial Metrics
Revenue
5.7M
Net Income
-5.2M
EPS (Diluted)
$-1.08
Free Cash Flow
-11.1M
Total Assets
30.9M
Cash
16.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-94.1%
Net Margin
-91.1%
ROE
-24.0%
ROA
-16.8%
FCF Margin
-194.6%
Balance Sheet & Liquidity
Current Ratio
3.57x
Quick Ratio
3.57x
Debt/Equity
0.00x
Debt/Assets
30.0%
Interest Coverage
-53.53x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T07:40:21.019239 |
Data as of: 2026-03-31 |
Powered by Claude AI